Breast Cancer

Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), discusses the MA.17R study for patients with breast cancer.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the ATEMPT trial for patients with HER2-positive breast cancer.

Topline results from the MONALESSA-7 trial showed that ribociclib met its primary endpoint for progression-free survival in premenopausal women with hormone-receptor

Melanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).

Laura J. van’t Veer, PhD, discusses determining more accurate methods of treatment for patients with early- and late-state breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.

Antineoplastic drug therapy has been delivered by the oral route since the earliest days of the modern chemotherapeutic era.

Michelle E. Melisko, MD, discusses a variety of pivotal trials with adjuvant hormonal therapy and other developments in the treatment of patients with ER-positive breast cancer.

A new generation of more selective inhibitors of CDK4 and CDK6 has entered the clinic in combination therapies for patients with breast cancer. These agents also are being investigated in patients with KRAS-mutant malignancies.

Elizabeth A. Mittendorf, MD, PhD, discusses the evolving neoadjuvant treatment landscape and other developments in the field of HER2-postive breast cancer.

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses late recurrence in patients with hormone receptor (HR)-positive breast cancer.

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses CDK4/6 inhibitors for patients with breast cancer.

Laura van ’t Veer, PhD, Leader of the Breast Oncology Program, and director of Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the guidelines for genetic testing in breast cancer.

Denise A. Yardley, MD, discusses the promise of CDK4/6 inhibitors in estrogen receptor–positive breast cancer, and the potential with immunotherapy agents.

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biomarker research in breast cancer.

Ten-year results from the TEAM trial on exemestane alone and sequential treatment with tamoxifen followed by exemestane for postmenopausal women with hormone receptor-positive breast cancer showed they were reasonable treatment options.

Rachel A. Freedman, MD, discusses treating patients with HER2-positive breast cancer who develop CNS metastases, and the promise that neratinib holds in this patient population.

Erika P. Hamilton, MD, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of PARP inhibitors in patients with triple negative breast cancer (TNBC).

The FDA has granted a priority review to a supplemental New Drug Application for olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer.

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.